xpertsystems/hconc001-sample

一个完全合成的、多模态乳腺癌队列，覆盖完整的临床路径：包括AJCC第8版T/N/M分期、PAM50分子亚型分类（Luminal A/B、HER2-Enriched、Triple-Negative）、全面的IHC生物标志物（ER/PR/HER2状态及Allred评分、HER2 FISH/IHC）、种系遗传学（BRCA1/BRCA2/PALB2致病性变异）、基因组分析（Oncotype DX复发评分、MammaPrint、PAM50、肿瘤突变负荷、PD-L1 CPS、PIK3CA突变、HRD评分）、治疗方案（手术、新辅助/辅助化疗、HER2靶向治疗、激素治疗、CDK4/6抑制剂、免疫治疗、PARP抑制剂）、生存结果（总生存期、无病生存期、乳腺癌特异性生存期、复发部位）、多模态成像（乳腺X线摄影BI-RADS、MRI、PET/CT、骨扫描）、合并症、实验室检查和液体活检（ctDNA分数、变异基因、拷贝数变异）。该数据集旨在直接用于分析、建模、演示和教育，同时保持100%合成性——无真实患者数据、无个人健康信息、无重新识别风险。A fully synthetic, multimodal breast cancer cohort spanning the complete clinical pathway: AJCC 8th Edition T/N/M staging, PAM50 molecular subtype classification (Luminal A/B, HER2-Enriched, Triple-Negative), comprehensive IHC biomarkers (ER/PR/HER2 with Allred scores and HER2 FISH/IHC), germline genetics (BRCA1/BRCA2/PALB2), genomic profiling (Oncotype DX, MammaPrint, PAM50, TMB, PD-L1 CPS, HRD score, PIK3CA), treatment protocols (surgery, neoadjuvant/adjuvant chemo, HER2-targeted, hormonal, CDK4/6, immunotherapy, PARP), survival outcomes (OS, DFS, BCSS, recurrence with site), multimodal imaging (mammography BI-RADS, MRI, PET/CT, bone scan), comorbidities, labs, and liquid biopsy (ctDNA fraction, variant genes, copy number alterations). Built to be drop-in usable for analytics, modeling, demos, and education while remaining 100% synthetic — no real patient data, no PHI, no re-identification risk.